DCH Health System Names Medline as Primary Distribution Partner

Medline today announced it has entered a multi-year prime vendor partnership with DCH Health System (DCH) to serve the healthcare needs of the west Alabama communities. DCH had partnered with a different distributor for more than 20 years, and with this change, Medline will exclusively provide an extensive portfolio of essential medical supplies and solutions across the DCH system’s three acute care facilities – DCH Regional Medical Center, Northport Medical Center and Fayette Medical Center. The two organizations will collaborate to identify new strategies for enhancing patient outcomes and streamlining supply chain operations.

“We are pleased to enter into this new partnership with Medline,” said Jeromie Atkinson, vice president of supply chain for the DCH Health System. “Medline’s approach and services look to be an ideal match to help us to better adopt best practices and more efficiently serve the needs of our system.”

Working with DCH supply chain leadership, Medline will support the system’s mission to balance cost and value by optimizing supply chain practices across the healthcare provider’s operations. Under the agreement’s terms, DCH can easily monitor key metrics such as item utilization, contract compliance, price accuracy, and spend by product categories through Medline’s advanced analytics platforms.

“Medline appears to be best positioned to help their customers by providing more clarity and advanced warning of supply disruptions. We all painfully learned that the COVID pandemic wasn’t just some bodily virus, but also a pandemic in our supply chains,” said DCH Supply Chain Director Dave Ryan. “Medline’s ability to give us some advanced warning is very important, allowing us time to react, plan and execute alternative solutions.”

The DCH system will be serviced by Medline’s state-of-the-art distribution network, utilizing routine MedTrans fleet deliveries of lowest unit of measure (LUM) totes, arriving at DCH supply rooms “put-away-ready” to drive greater staff efficiency.

Medline is committed to helping enable DCH to provide compassionate care and advance the caring of patients by understanding and addressing the system’s supply chain needs,” said Tom Reynolds, vice president of sales for Medline. “We look forward to working closely with the DCH team to optimize operations, provide reliable, superior service and prove ourselves as a strategic partner.”

SourceMedline

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”